Live tape
Top 8, mentions 7d17,662MSFT3,333 mentions▲ +0.08GOOGL2,706 mentions▲ +0.05AAPL2,321 mentions▲ +0.07META2,242 mentions▲ +0.04SPCX1,997 mentions▲ +0.06SNDK1,870 mentions▲ +0.06NVDA1,761 mentions▲ +0.07QQQ1,432 mentions▲ +0.04

Equity · Healthcare

BBIO

BridgeBio Pharma, Inc. · NasdaqGS

$85.00 +1.02% 1D Finazon · prior-day close · Jul 28, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of BBIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 63 sessions over that window: $68.57 on 1 May 2026 through $85.00 on 28 July 2026. Finazon · prior-day close.

Market cap $16.6B
52-week range $43.00 – $90.00
Avg volume 702.1K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

BBIO insider trades

SEC Form 4 · last 90 days · newest reported trade 9 Jul 2026
Open-market buys 0
Open-market sells 14
Net sold $35.14M
Non-trade filings 23
Date Insider Type Shares Value
09 Jul 2026 Cook Jennifer E. Director Sell 148,589 $13.16M
09 Jul 2026 Ellis Andrea Director Sell 17,167 $1.44M
24 Jun 2026 Cook Jennifer E. Director Sell 37,167 $2.60M
23 Jun 2026 Valantine Hannah Director Sell 2,196 $151K
23 Jun 2026 Cook Jennifer E. Director Sell 2,196 $151K

Showing the 12 most recent of 37 filings in this window. The figures above count all of them.

Compensation mechanics (7 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
09 Jul 2026 Cook Jennifer E. Director Option exercise 148,589 $3.71M
09 Jul 2026 Ellis Andrea Director Option exercise 17,167 $288K
24 Jun 2026 Cook Jennifer E. Director Option exercise 37,167 $457K
22 Jun 2026 AGUIAR ERIC Director Award 3,990
22 Jun 2026 Satvat Ali J. Director Award 3,990
22 Jun 2026 Dachille Douglas A. Director Award 3,990
22 Jun 2026 MCCORMICK FRANK Director Award 3,990

BBIO reported financials

SEC EDGAR XBRL

BBIO reported revenue of $502.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$724.9M.

Figure Reported Period
Revenue $502.1M 31 Dec 2025 fiscal year
Net income to common shareholders −$724.9M 31 Dec 2025 fiscal year
Diluted EPS −$3.78 31 Dec 2025 fiscal year
Total assets $1.4B 31 Mar 2026 at period end
Total equity −$2.3B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

BBIO earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $-0.84 $195M
31 Dec 2025 FY 2025 $-3.78 $502M
30 Sep 2025 Q3 2025 $-0.95 $121M
30 Jun 2025 Q2 2025 $-0.95 $111M

Reported figures & scheduled dates · SEC EDGAR filings

BBIO institutional holders

SEC Form 13F

12 of the 45 institutional funds we track reported a BBIO position for the quarter ended 31 Mar 2026 — a combined $1.7B; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) −17.7% shares 11,842,434 $879.4M
Citadel Advisors Added +354.6% shares 3,173,940 $235.7M
Two Sigma Investments Added +60.3% shares 3,120,631 $231.7M
D. E. Shaw & Co. Held (±25%) +15.0% shares 2,545,486 $189.0M
Millennium Management Added +1,631.0% shares 633,283 $47.0M
Renaissance Technologies New position 365,772 $27.2M
Fisher Asset Management Added +51.3% shares 351,628 $26.1M
Balyasny Asset Management Added +49.4% shares 350,096 $26.0M
Marshall Wace Added +347.7% shares 334,382 $24.8M
Bridgewater Associates Added +501.0% shares 259,459 $19.3M

Source: SEC EDGAR 13F filings

BBIO fails-to-deliver

SEC CNS data

On 30 Jun 2026, 1,697,839 shares of BBIO failed to deliver (about $122.3M) — the latest of 4 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 1,697,839 $122.3M 0.867%
29 Jun 2026 1,647,278 $115.7M 0.841%
26 Jun 2026 93 $6K <0.001%
25 Jun 2026 522 $36K <0.001%
15 Jun 2026 187 $12K <0.001%

Source: SEC fails-to-deliver (CNS) data